Previous 10 | Next 10 |
home / stock / tpst / tpst articles
BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (NASDAQ:TPST), a clinical-stage biotechnology company developing...
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results. Astra Space, Inc. (N...
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 50 points on Thursday. The Dow traded up 0...
Gainers Biocept, Inc. (NASDAQ: BIOC) shares surged 91.8% to $0.98 in pre-market trading after falling over 6% on Tuesday. Biocept recently filed ...
Tempest Therapeutics, Inc. (NASDAQ: TPST) shares are continuing a recent streak of volatility Tuesday. TPST shares are up nearly 3500% over the las...
Gainers OpGen, Inc. (NASDAQ: OPGN) jumped 593% to $2.33 following two SEC filings from the precision medicine company. The company has received a...
U.S. stocks traded slightly lower this morning, following the release of CPI data on Thursday. Following the market opening Thursday, the Dow trade...
Gainers OpGen, Inc. (NASDAQ: OPGN) shares rose 432% to $1.79 in pre-market trading. Opgen said on Oct. 6, unit Curetis GMBH received payment of 75...
Tempest Therapeutics Inc (NASDAQ: TPST) shares are trading lower Thursday. The company sold shares as part of a previously announced offe...
News, Short Squeeze, Breakout and More Instantly...
Tempest Therapeutics Inc. Company Name:
TPST Stock Symbol:
NASDAQ Market:
Tempest Therapeutics Inc. Website:
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain in survival follow up 0.65 hazard ratio, maintained since 0.59 observed in primary analysis 10 months earlier Early and persistent separation of survival curves ...
BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced the company plans to report new data from the global ran...